Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 33 clinical trials
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

  • 06 Nov, 2021
  • 4 locations
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

  • 15 Mar, 2022
  • 20 locations
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to …

measurable disease
monoclonal antibodies
  • 25 Mar, 2022
  • 19 locations
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

measurable disease
stem cell transplantation
  • 09 Mar, 2022
  • 22 locations
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists

chronic lymphocytic leukemia
marginal zone lymphoma
waldenstrom's macroglobulinemia
follicular lymphoma
  • 24 Mar, 2022
  • 15 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

carcinoma in situ
major surgery
solid tumor
  • 09 May, 2022
  • 925 locations
CMP-001 for Relapsed and Refractory Lymphoma

patients with relapsed and refractory lymphomas.

measurable disease
therapeutic agents
hodgkin's disease
  • 02 May, 2022
  • 1 location
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

measurable disease
refractory classical hodgkin lymphoma
refractory b-cell non-hodgkin lymphoma
  • 05 May, 2022
  • 9 locations
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to …

measurable disease
bone marrow procedure
hodgkin's disease
neutrophil count
  • 29 Jan, 2022
  • 9 locations
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: cohort 1: DLBCL patients cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractory/Relapse status will be determined by PET-CT central …

  • 21 Jun, 2021
  • 15 locations